Screening for Neuroendocrine Tumors Is Recommended for NF1 Patients
A study on pheochromocytoma and paraganglioma associated with neurofibromatosis type 1 highlights how screening for these malignancies is important. (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Can Simple Clinical Factors Predict Metastatic Potential of Neuroendocrine Tumors?
Researchers have developed a clinical prediction model for the metastatic potential of pheochromocytoma and paraganglioma. (Source: CancerNetwork)
Source: CancerNetwork - August 24, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

FDA approves Progenics' drug for rare tumors
The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors, pheochromocytoma or paraganglioma, and require anti-cancer therapy (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 31, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Azedra for Rare Adrenal Tumors
TUESDAY, July 31, 2018 -- Azedra (iobenguane) has been approved by the U.S. Food and Drug Administration to treat people 12 and older with rare adrenal gland tumors (pheochromocytoma or paraganglioma) that can't be surgically removed and have spread... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first non-surgical treatment for 2 rare cancers
The Food and Drug Administration on Tuesday approved the first ever non-surgical treatment for the rare neuroendocrine cancers: pheochromocytoma and paraganglioma. The approval for Azedra, a drug developed by Progenics Pharmacecuticals of Tarrytown, N.Y., was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania in Philadelphia. “This is a true breakthrough," said Dr. Daniel A. Pryma, an associate professor of radiology and radiation… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 31, 2018 Category: American Health Authors: John George Source Type: news

Therapy for Rare Cancers receives FDA approval following trials at Penn's Abramson Cancer
(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma. The approval was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania and was granted to Progenics Pharmaceuticals for AZEDRA (iobenguane I131). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 31, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves Drug for Rare Adrenal Tumors
(MedPage Today) -- Iobenguane I 131 active in pheochromocytoma, paraganglioma (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 30, 2018 Category: Primary Care Source Type: news

Pheochromocytoma/Paraganglioma and Cancer Metabolism Pheochromocytoma/Paraganglioma and Cancer Metabolism
A better understanding of the metabolic pathophysiology in pheochromocytomas/paragangliomas may lead to more targeted treatment for these tumors.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Pheochromocytoma: A Genetic and Diagnostic Update Pheochromocytoma: A Genetic and Diagnostic Update
Improved diagnostic tools offer earlier and more accurate detection of pheochromocytomas and paragangliomas.Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Penn-led trial shows AZEDRA can be effective, safe for treatment of rare neuroendocrine tumors
(University of Pennsylvania School of Medicine) A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2018 Category: Cancer & Oncology Source Type: news

Cabozantinib Promising in Malignant Adrenal Gland Tumors
(MedPage Today) -- Longer PFS in patients with pheochromocytomas, paragangliomas (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 21, 2018 Category: Endocrinology Source Type: news

Cabozantinib Looks Promising for Malignant Pheochromocytoma Cabozantinib Looks Promising for Malignant Pheochromocytoma
Tyrosine kinase inhibitor may offer several benefits to patients with malignant pheochromocytomas and paragangliomas, very rare forms of cancer that are difficult to treat.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Aspects of SDHA-Related Pheochromocytoma and Paraganglioma Aspects of SDHA-Related Pheochromocytoma and Paraganglioma
A better understanding of germline SDHA variants and mutations may allow for the earlier detection of paragangliomas.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Dec. 29, 2017 -- (Healthcare Sales & Marketing Network) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the... Biopharmaceuticals, Oncology, FDA Progenics Pharmaceuticals, AZEDRA, iobenguane, Pheochromocytoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 29, 2017 Category: Pharmaceuticals Source Type: news

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 29, 2017 Category: Drugs & Pharmacology Source Type: news

Progenics Pharmaceuticals Completes Submission of NDA for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it has completed the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 2, 2017 Category: Drugs & Pharmacology Source Type: news

Pheochromocytoma and Paraganglioma in Children
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 26, 2017 Category: General Medicine Source Type: news

New mutations related to hereditary neuroendocrine tumors
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The presence of a germline mutation in the GOT2 gene found in a patient with metastasis gives rise to increased activity of the encoder enzyme. Furthermore, the authors describe extraordinarily rare mutations in two patients: one in the SDHC gene and another in the IDH1. Finally, by way of an extension study focused on more than 60 patients with these neuroendocrine tumors, a new susceptibility gene, IDH3B, associated with the development of paragangliomas was identified. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 20, 2017 Category: Cancer & Oncology Source Type: news

New mutations related to hereditary neuroendocrine tumours
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The presence of a germline mutation in the GOT2 gene found in a patient with metastasis gives rise to increased activity of the encoder enzyme. Furthermore, the authors describe extraordinarily rare mutations in two patients: one in the SDHC gene and another in the IDH1. Finally, by way of an extension study focused on more than 60 patients with these neuroendocrine tumours, a new susceptibility gene, IDH3B, associated with the development of paragangliomas was identified. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2017 Category: International Medicine & Public Health Source Type: news

Wait - and - Scan Strategy Feasible for Head, Neck Paraganglioma
Large group of tumors found not to grow, although they did elicit complications (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 17, 2017 Category: Cancer & Oncology Tags: Neurology, Oncology, Pathology, Radiology, Surgery, Journal, Source Type: news

Treatment of Head and Neck Paragangliomas Treatment of Head and Neck Paragangliomas
Is first-line treatment for carotid body tumors the same as that for jugular and vagal paragangliomas?Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Preoperative Management for Phaeochromocytoma/Paraganglioma Preoperative Management for Phaeochromocytoma/Paraganglioma
Find out what the available evidence tells us about the preoperative management of patients with phaeochromocytomas and paragangliomas.Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

New study links'mastermind' gene to rare cancer-causing tumor
Scientists have discovered a new " mastermind fusion gene " may be associated with a rare cancer-causing tumor -- pheochromocytomas ( " pheo " ) and paragangliomas -- according to a study. This breakthrough discovery could lead to more precise treatment as well as a better understanding of cancer itself. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 13, 2017 Category: Science Source Type: news

In-depth gene search reveals new mutations, drug targets in rare adrenal tumors
(University of Pennsylvania School of Medicine) Casting one of the largest genomic nets to date for the rare tumors of the autonomic nervous system known as pheochromocytoma and paraganglioma (PCC/PGL) captured several new mutations driving the disease that could serve as potential drug targets, researchers from Penn Medicine and other institutions reported this week in Cancer Cell. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2017 Category: Global & Universal Source Type: news

Perioperative Care of PhaeochromocytomaPerioperative Care of Phaeochromocytoma
This article reviews the essentials of perioperative care and monitoring in patients with pheochromocytomas and paragangliomas. BJA Education (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 7, 2016 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Adrenoceptor Blockade for Hormonally Functional Pheo/PGLAdrenoceptor Blockade for Hormonally Functional Pheo/PGL
A new study examines whether patients with hormonally functional pheochromocytomas and paragangliomas (pheo/PGLs) are receiving the appropriate pharmacological treatment. Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Published in Hormone and Metabolic Research, a study found that paediatric patients with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times more likely to also carry a diagnosis of ADHD. Clinical Endocrinology News (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 20, 2016 Category: Endocrinology Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Pediatric patients diagnosed with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times as likely to also carry a diagnosis of attention deficit hyperactivity disorder (ADHD),... (Source: Pediatric News)
Source: Pediatric News - May 19, 2016 Category: Journals (General) Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Pediatric patients diagnosed with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times as likely to also carry a diagnosis of attention deficit hyperactivity disorder (ADHD),... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - May 19, 2016 Category: Endocrinology Source Type: news

TERT promoter mutations in adrenal tumours
The telomerase reverse transcriptase gene (TERT) is essential for telomere stabilization and cell immortalization. A role for TERT promoter mutations C228T and C250T has been demonstrated in aggressive human cancer. The underlying mechanisms of telomerase activation is not known in adrenal tumors. Liu and colleagues assessed C228T and C250T TERT mutations, finding that TERT promoter mutation C228T is a recurrent event associated with adrenocortical carcinoma, but rarely occurs in paraganglioma or pheochromocytoma. The involvement of the TERT gene in adrenocortical carcinoma is a new finding. Read the full article at Liu e...
Source: Society for Endocrinology - June 26, 2014 Category: Endocrinology Source Type: news

Endocrine Society First to Address Rare Adrenal-Tumor CareEndocrine Society First to Address Rare Adrenal-Tumor Care
New clinical practice guidelines are the first ever to address management of patients with pheochromocytoma and paraganglioma, rare adrenal tumors that can be fatal if not diagnosed. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 5, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Exome sequencing in phaeochromocytoma/paraganglioma
In this study, McInerney-Leo et al. have assessed whether whole exome sequencing (WES), using an off-the-shelf exome capture platform rather than designing individual targeted assays, is a sensitive, time- efficient and cost-effective way to offer genetic testing in a population of individuals with established diagnosis of PCC/PGL. They also evaluated the target capture of the currently available exome capture platforms for exons of the known PCC/PGL genes. They demonstrate that WES accurately diagnosed all mutations in all 11 patients with PCC/PGL in whom mutations had been detected previously by Sanger sequencing. Furth...
Source: Society for Endocrinology - January 27, 2014 Category: Endocrinology Source Type: news

Exome sequencing in phaeochromocytoma/paraganglioma
In this study, McInerney-Leo et al. have assessed whether whole exome sequencing (WES), using an off-the-shelf exome capture platform rather than designing individual targeted assays, is a sensitive, time- efficient and cost-effective way to offer genetic testing in a population of individuals with established diagnosis of PCC/PGL. They also evaluated the target capture of the currently available exome capture platforms for exons of the known PCC/PGL genes. They demonstrate that WES accurately diagnosed all mutations in all 11 patients with PCC/PGL in whom mutations had been detected previously by Sanger sequencing. Furth...
Source: Society for Endocrinology - January 24, 2014 Category: Endocrinology Source Type: news

Long-term prognosis in pediatric pheochromocytoma
A third of patients with paraganglial tumors, pheochromocytoma, and paraganglioma, carry germline mutations in one of the susceptibility genes, RET, VHL, NF1, SDHAF2, SDHA, SDHB, SDHC, SDHD, TMEM127, and MAX. Despite increasing importance, data for long-term prognosis are scarce in pediatric presentations. Using the European–American–Pheochromocytoma–Paraganglioma Registry as a platform, Bausch and colleagues report the first and only population-based study of longterm outcomes in pediatric pheochromocytoma. Read the full article at Bausch et al. (2014) Endocrine-Related Cancer 21; 17&nda...
Source: Society for Endocrinology - January 24, 2014 Category: Endocrinology Source Type: news

Gene susceptibility testing in phaeochromocytoma and paraganglioma
Recent studies have suggested that around one-third of individuals with phaeochromocytoma or paraganglioma have an inherited genetic predisposition, prompting some calls for genetic testing in all patients with phaeochromocytoma or paraganglioma. Such a strategy is expensive, and variation between populations is large. Jafri and colleagues analysed data from a 10-year period in the West Midlands PPGL/HNPGL database, finding that clinical risk factors (positive family history, multiple tumours, earlier age at onset) could be used to target genetic testing in a cost-effective manner, though universal testing would be require...
Source: Society for Endocrinology - June 12, 2013 Category: Endocrinology Source Type: news

Level of tumor protein indicates chances cancer will spread
Contact:Robert Bock or Marianne Glass Miller 301-496-5133Level of tumor protein indicates chances cancer will spreadNIH researchers seek to develop test to guide treatmentResearchers at the National Institutes of Health and the University of Hong Kong have discovered that high levels of a particular protein in cancer cells are a reliable indicator that a cancer will spread.By measuring the protein’s genetic material in tumors that had been surgically removed from patients, along with measuring the genetic material from surrounding tissue, the researchers could predict at least 90 percent of the time whether a cancer ...
Source: Kidney Cancer Association - February 2, 2011 Category: Urology & Nephrology Source Type: news

Level of tumor protein indicates chances cancer will spread
Contact: Robert Bock or Marianne Glass Miller 301-496-5133 Level of tumor protein indicates chances cancer will spread NIH researchers seek to develop test to guide treatment Researchers at the National Institutes of Health and the University of Hong Kong have discovered that high levels of a particular protein in cancer cells are a reliable indicator that a cancer will spread. By measuring the protein’s genetic material in tumors that had been surgically removed from patients, along with measuring the genetic material from surrounding tissue, the researchers could predict at least 90 percent of the time whether a c...
Source: Kidney Cancer Association - February 2, 2011 Category: Urology & Nephrology Source Type: news